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Abstract
Background: Cytokines are involved in the development of chronic diseases, including cancer. It is important to
evaluate the temporal reproducibility of cytokines in plasma prior to conducting epidemiologic studies utilizing
these markers.
Findings: We assessed the temporal reliability of CRP, 22 cytokines and their soluble receptors (IL-1a, IL-1b, IL-1RA,
IL-2, sIL-2R, IL-4, IL-5, IL-6, sIL-6R, IL-7, IL-8, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17, TNFa, sTNF-R1, sTNF-R2, IFNa,
IFNg) and eight growth factors (GM-CSF, EGF, bFGF, G-CSF, HGF, VEGF, EGFR, ErbB2) in repeated EDTA plasma
samples collected an average of two years apart from 18 healthy women (age range: 42-62) enrolled in a
prospective cohort study. We also estimated the correlation between serum and plasma biomarker levels using 18
paired clinical samples from postmenopausal women (age range: 75-86).
Twenty-six assays were able to detect their analytes in at least 70% of samples. Of those 26 assays, we observed
moderate to high intra-class correlation coefficients (ICCs)(ranging from 0.53-0.89) for 22 assays, and low ICCs
(0-0.47) for four assays. Serum and plasma levels were highly correlated (r > 0.6) for most markers, except for seven
assays (r < 0.5).
Conclusions: For 22 of the 31 biomarkers, a single plasma measurement is a reliable estimate of a woman’s
average level over a two-year period.
Introduction
Cytokines and growth factors regulate proliferation,
apoptosis, and angiogenesis, processes implicated in the
development and progression of a number of chronic
diseases. Elevated circulating levels of certain inflamma-
tion markers, namely C-reactive protein (CRP) and
interleukin (IL)-6, have been associated with subsequent
risk of cardiovascular disease [1,2] diabetes [3,4], and
cancer [5]. Studies investigating the influence of biomar-
kers on subsequent risk of disease must obtain biologi-
cal samples collected prospectively to minimize bias due
to the influence of existing disease on marker levels. In
most studies, prospectively collected samples are
obtained from established cohorts, which often have
only a single blood sample from each participant.
Although basal cytokine and growth factor levels are
determined in part by heritability [6,7], they are also
likely to be influenced by other factors. Since cytokines
and growth factors vary in both acute (e.g. infection,
injury, etc.) and chronic inflammatory conditions (e.g.
autoimmune disease, obesity, cardiovascular disease,
cancer), it is important to determine whether circulating
marker levels are reflective only of the short term phy-
siological state or if they represent an individual’sa v e r -
age levels over time, relative to other individuals.
The Luminex methodology is well-suited for analyses
of a large number of banked samples from prospective
cohort studies because it allows for simultaneous mea-
surement of multiple analytes, thereby reducing sample
volume requirements, cost, and labor compared to other
earlier methods (e.g. single analyte ELISAs)[8]. Our
group has previously shown that a number of inflamma-
tion markers and growth factors measured using Lumi-
nex technology in stored serum samples, including IL-1b,
IL-1 receptor antagonist (Ra), IL-2, IL-4, IL-5, IL-6,
IL-10, IL-12p40, IL-12p70, TNF, soluble TNF-receptor
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(HGF), and epidermal growth factor receptor (EGFR)
have sufficient temporal reliability to be used for epide-
miological studies (intraclass correlation (ICC) ≥ 0.55)[9].
Another group reported similarly moderate to high ICCs
(ranging from 0.57-0.89) for serum levels of TNF, IL-1b,
IL-6, IL-8, IL-10, CRP, and HGF in a study of 48 healthy
Chinese men [10]. To our knowledge only one study
evaluated variation in a small number of plasma cyto-
kines (type of anticoagulant unknown) measured using
Luminex and found that temporal reliability was high for
IL-1a, IL-4, IL-8, and IL-10, moderate for TNFa,a n d
low for IL-1RA [11]. The purpose of the present study
was to evaluate the temporal reliability of a broad range
of cytokines and growth factors in EDTA plasma
samples. We also examined the correlation between
serum and plasma cytokines measured using Luminex
technology.
Materials and methods
Study Design
Study subjects were from the Northern Sweden Health
and Disease Study (NSHDS) cohort, which has been
described previously [12]. Briefly, since 1985, partici-
pants between the ages of 30-70 have been recruited
from population-based cardiovascular and/or breast
screening programs in Northern Sweden. At enrollment,
participants provided 20 mL of fasting peripheral venous
blood, drawn with tubes containing EDTA as an anti-
coagulant. A second EDTA plasma sample has since
been collected from a subset of the cohort. Samples
were drawn, processed, and stored under a standardized
protocol, in which they were centrifuged immediately
after blood draw, and plasma was aliquotted and stored
at -80°C.
Eighteen female NSHDS participants between the ages
of 42 and 62 who provided two blood samples at least
1-3 years apart (n = 36 samples (18 pairs)) are included
in the present study to assess temporal reproducibility
of cytokine measurements in EDTA plasma samples
(Figure 1). Subjects were free of invasive cancer or other
chronic diseases. All samples were run on the same
well-plate to minimize laboratory batch effects. To esti-
mate intra-batch coefficients of variation (CVs), dupli-
cate EDTA plasma samples from the first blood
donation for 8 subjects were also included on the same
well-plate.
To assess the influence of sample type on the cytokine
measurements, paired EDTA plasma and serum samples
were collected from 18 postmenopausal women (age
range: 75 to 86) who were participating in a clinical
research study at the University of Umeå in Sweden
(Figure 1). All subjects were free of cancer and cardio-
vascular disease. At enrollment, 20 mL non-fasting
blood samples were collected into tubes containing no
anticoagulant (serum) and tubes containing EDTA as an
anti-coagulant (plasma). Sample processing was com-
pleted immediately after blood collection, under the
same standardized procedure as the NSHDS samples,
and serum and EDTA plasma fractions have since been
stored at -80°C.
Cytokine Measurements
We measured CRP, 22 cytokines and their soluble
receptors (IL-1a, IL-1b, IL-1RA, IL-2, sIL-2R, IL-4, IL-5,
IL-6, sIL-6R, IL-7, IL-8, IL-10, IL-12p40, IL-12p70,
IL-13, IL-15, IL-17, TNFa,s T N F - R 1 ,s T N F - R 2 ,I F N - a,
IFN-g), and 8 growth factors (granulocyte macrophage
colony stimulating factor (GM-CSF), epidermal growth
factor (EGF), basic fibroblast growth factor (bFGF),
G-CSF, HGF, vascular endothelial growth factor
(VEGF), EGFR, and human epidermal growth factor
receptor 2 (ErbB2)) using Luminex multiplex bead-
based technology. For 11 biomarkers (IL-1b,I L - 2 ,I L - 4 ,
IL-5, IL-6, IL-7, IL-8, IL-10, IL-13, TNFa,I F N g), both
regular [8] and high-sensitivity (hs) assays [13] were per-
formed, resulting in a total of 42 measurements per
sample. Thirteen biomarkers (hsIL-1b,h s I L - 2 ,h s I L - 4 ,
hsIL-5, hsIL-6, hsIL-7, hsIL-8, hsIL-10, hsIL-12p70,
hsIL-13, hsTNFa,h s I F N g, and hsGM-CSF) were mea-
sured using a high-sensitivity (hs) kit from Linco/Milli-
pore, CRP was measured using the CVD-2 kit from
Linco/Millipore, EGFR and ErbB2 were measured with a
kit developed in-house, and the other 27 markers were
measured using a regular-sensitivity kit from Biosource
International (Camarillo, CA). The assays were run in
accordance with manufacturers’ protocols and methods
have been reported previously [9]. The lower limit of
detection (LLD) and the coefficient of variation (CV) for
each marker are presented in Table 1.
Statistical analyses
Cytokine fluorescence intensity (raw data) values were
set to missing if they were below background. Values
were log-transformed to reduce departures from the
normal distribution. The intraclass correlation coeffi-
cient (ICC) was used to assess temporal reliability. The
ICC estimates the fraction of the total variation (within-
plus between-subject variation) due to between-subject
variation [14]. The ICC can take on any value between
zero and one; values close to zero are indicative of no
correlation between the repeated measurements, while
values close to one indicate high replicability of a given
subject’s measurements over time. A random effects
one-way analysis of variance model was used to estimate
the within- and between-subject variance components.
ICCs were only calculated for markers that were above
the lower limit of detection (LLD) in at least 70% of the
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markers which required extrapolation below the stan-
dard curve for a large percentage (> 40%) of the sam-
ples. While these markers could potentially be used in
future epidemiological studies, the high percentage of
missing or extrapolated values in the present study
would have limited the interpretation of the ICCs. Our
ap r i o r icriteria for inflammation markers to be consid-
ered for use in our epidemiological study of ovarian can-
cer risk was an ICC ≥ 0.55. A number of biomarkers
with ICCs in this range have been shown to be consis-
tent predictors of disease in epidemiological studies,
such as postmenopausal endogenous estrogens (ICCs
ranging from 0.5-0.7 over a 2-3 year period) [15-17],
blood pressure (0.6 for systolic and diastolic over a 2-4
year period) [17,18], and serum cholesterol (0.6-0.7 over
a 1-2 year period) [17,19].
To compare plasma and serum values, we computed
the relative difference between each plasma/serum pair
(plasma value minus serum value divided by plasma
value) and report the median relative difference as a per-
centage. The Wilcoxon signed-rank test was used to test
whether marker values were systematically higher in one
of the sample types. Spearman correlation coefficients
(rs) were calculated for EDTA plasma vs. serum samples
for the 18 participants from the clinical research study.
For the 11 cytokines that were measured in EDTA
plasma using both high-sensitivity and regular assays,
Spearman correlation coefficients were calculated to
assess the correlation between the assays. To increase
the sample size for this analysis, we used all 54 plasma
samples which had been measured by both assays. We
were concerned that the high correlation between
plasma samples collected annually from the NSHDS
participants might bias the correlation coefficients.
Thus, we also used a bootstrap method to randomly
select one of the two plasma samples for each subject
from the NSHDS study to create a group of 36 mutually
independent samples (n = 18 of the 36 samples from
NSHDS plus the 18 plasma samples from the clinical
research study). We repeated this step 100 times and
calculated the average Spearman correlation coefficient.
All study subjects provided written informed consent
to participate in the study. The Regional Ethical Com-
mittee of the University of Umeå, Sweden, and the
Swedish Data Inspection Board reviewed and approved
this study.
Results
Temporal Reliability of EDTA Plasma Cytokines and
Growth Factors
The mean age of the study subjects from the NSHDS
study at their initial blood donation was 55.6 years and
all subjects were of European descent. EDTA plasma
samples from the first and second blood donations were
stored for an average of 17.8 years and 15.6 years,
respectively. The average time between blood donations
was 2.1 years (range: 1.7-3.7 years). Four participants
Figure 1 Study Design.
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donation.
The lower limits of detection, percentage of samples
above the lower limit of detection, and median cytokine
values are shown in Table 1 for the 26 marker assays
which yielded detectable values for more than 70% of
the samples. Detection proportions and median values
were similar for both visits (Table 1). Not included in
the table are results for 16 marker assays which yielded
undetectable values for more than 30% of the samples
(IL-1b, IL-1RA, IL-5, IL-6, IL-17, VEGF) and/or
required extrapolation below the lowest point on the
standard curve for a high percentage of the samples
(about 40% for IL-8 and bFGF and 60-95% for IL-1a,
IL-2, IL-7, IL-10, IL-13, IL-15, TNFa,a n dE G F ) .
Markers included in Table 1 had no extrapolated values
except for one sample for IFNa.
CVs, ICCs, and 95% CIs for the ICCs are also shown
in Table 1. These marker assays had satisfactorily low
CVs (≤ 6.4%), indicating they can be reproducibly mea-
sured in EDTA plasma samples. Twenty-two of the 26
biomarker assays (hsIL-1b, hsIL-2, sIL-2R, hsIL-4,
hsIL-5, hsIL-6, sIL-6R, hsIL-7, hsIL-8, hsIL-10, IL-
12p40, hsIL-12p70, hsIL-13, CRP, IFNa,h s I F N g,
hsTNFa, sTNF-R2, EGFR, ErbB2, G-CSF, and HGF)
had moderate to high ICCs, ranging from 0.53-0.89,
which suggests that these markers are temporally
reproducible in women over a 1-3 year period. Of the
four marker assays with low ICCs (0.00 - 0.47), two
markers (IL-4 and IFNg)w e r ea l s om e a s u r e db y
Table 1 Temporal reproducibility of EDTA plasma biomarkers measured by Luminex xMap™, NSHDS subjects
a (n = 18
pairs)
Biomarker LLD First Sample Second Sample Intra-batch CV ICC (95% CI)
% Above LLD Median (25%, 75%) % Above LLD Median (25%, 75%)
hsIL-1b (pg/mL)
b 0.06 100 8.1 (5.5, 11.3) 100 8.0 (4.6, 10.1) 2.0% 0.73 (0.43-0.89)
hsIL-2 (pg/mL)
b 0.16 100 28.8 (18.9, 39.1) 100 31.3 (20.8, 39.9) 2.7% 0.80 (0.56-0.92)
sIL-2R (pg/ml)
c 30 100 652 (624, 789) 100 691 (624, 762) 1.0% 0.86 (0.68-0.95)
IL-4 (pg/mL)
c 5 100 140 (114, 163) 100 120 (109, 143) 1.6% 0.00 (-0.45-0.45)
hsIL-4 (pg/mL)
b 0.13 100 50.5 (31.4, 80.7) 100 42.4 (16.2, 83.0) 2.7% 0.70 (0.36-0.87)
hsIL-5 (pg/mL)
b 0.01 100 3.4 (1.8, 4.6) 100 3.2 (1.8, 4.2) 2.5% 0.73 (0.41-0.89)
hsIL-6 (pg/mL)
b 0.10 100 20.4 (15.9, 28.7) 100 18.4 (13.8, 24.3) 2.0% 0.81 (0.56-0.92)
sIL-6R (ng/mL)
c 0.024 100 29.0 (26.5, 42.6) 100 29.8 (25.2, 36.4) 0.3% 0.69 (0.36-0.87)
hsIL-7 (pg/mL)
b 0.12 100 10.1 (6.5, 15.7) 94.4 10.7 (6.1, 13.7) 3.3% 0.55 (0.14-0.80)
hsIL-8 (pg/mL)
b 0.11 100 9.3 (6.4, 11.8) 100 8.3 (5.3, 10.5) 1.6% 0.86 (0.68-0.95)
hsIL-10 (pg/mL)
b 0.15 100 40.7 (26.7, 57.2) 100 33.2 (15.8, 56.3) 2.1% 0.75 (0.46-0.90)
IL-12p40 (pg/mL)
c 15 100 410 (379, 471) 100 413 (402, 447) 0.7% 0.89 (0.73-0.96)
hsIL-12p70 (pg/mL)
b 0.11 100 32.3 (21.5, 46.5) 100 26.0 (11.8, 40.7) 2.1% 0.77 (0.50-0.91)
hsIL-13 (pg/mL)
b 0.48 100 45.7 (30.5, 51.9) 100 39.6 (15.4, 50.2) 3.0% 0.81 (0.56-0.92)
CRP (μg/mL)
b 0.000002 100 10.6 (3.1, 17.1) 100 8.5 (4.0, 16.9) 1.9% 0.76 (0.48-0.90)
IFNa (pg/mL)
c 15 100 45.8 (41.1, 70.7) 100 50.2 (37.8, 80.7) 5.1% 0.53 (0.11-0.79)
IFNg (pg/mL)
c 5 100 175 (108, 199) 100 118 (95.3, 162) 1.8% 0.00 (-0.45-0.45)
hsIFNg (pg/mL)
b 0.29 100 78.3 (42.6, 99.4) 100 65.0 (43.4, 103) 2.2% 0.72 (0.41-0.89)
hsTNFa (pg/mL)
b 0.05 100 8.0 (6.2, 11.2) 100 8.4 (5.8, 10.9) 1.9% 0.69 (0.36-0.87)
sTNF-R1 (ng/mL)
c 0.015 100 1.3 (1.2, 1.8) 100 1.2 (0.9, 1.6) 1.7% 0.31 (-0.16-0.67)
sTNF-R2 (ng/mL)
c 0.015 100 1.1 (0.72, 1.2) 100 0.9 (0.7, 1.1) 0.5% 0.68 (0.33-0.86)
Growth Factors
EGFR (ng/mL)
d 0.020 100 15.4 (14.1, 15.9) 100 15.3 (13.9, 16.6) 0.5% 0.93 (0.83-0.97)
ErbB2 (ng/mL)
d 0.017 100 3.4 (2.9, 3.6) 100 3.2 (3.0, 3.8) 0.5% 0.63 (0.26-0.84)
hsGM-CSF (pg/mL)
b 0.46 100 38.2 (29.6, 52.4) 100 33.5 (21.9, 39.9) 2.9% 0.47 (0.03-0.76)
G-CSF (pg/mL)
c 15 100 129 (108, 167) 100 129 (108, 160) 6.4% 0.75 (0.46-0.90)
HGF (pg/mL)
c 10 100 151 (101, 186) 100 196 (101, 278) 1.1% 0.74 (0.43-0.89)
Note: LLD = lower limit of detection as reported by the manufacturer, CVs are based on 8 blinded duplicates.
a Limited to the biomarkers for which more than 70% of all the samples were detectable. There were no extrapolated values for any of the markers included in
the table except for 1 sample for IFNa. Sixteen markers are not included because more than 30% of samples were undetectable (IL-1b, IL-1RA, IL-5, IL-6, IL-17,
VEGF), and/or a high percentage of samples were extrapolated below the lowest point on the standard curve (IL-1a, IL-2, IL-7, IL-8, IL-10, IL-13, IL-15, TNFa,E G F ,
bFGF).
b Kits from Linco/Millipore
c Kit from Biosource.
d Kit developed in-house.
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q u a t eI C C si nt h i ss t u d y( h s I L - 4a n dh s I F N g,T a b l e1 ) .
Comparison of EDTA Plasma versus Serum
Clinical research study subjects included in this report
provided paired EDTA plasma and serum samples. The
average age of the subjects at blood donation was 78.9
years and all subjects were of European descent. Sam-
ples were stored for an average of 10.9 years.
The percentage of samples above the LLD for EDTA
plasma and serum are shown for the clinical research
study participants in Table 2. The percentage of EDTA
plasma samples that could be detected was the same for
the clinical research subjects as for the NSHDS subjects.
Values were only extrapolated below the standard curve
for a small percentage (less than 14%) of samples for
hsIL-5, IFNa, and IL-6R. Marker measurements were
significantly higher in serum than EDTA plasma for
sIL-6R, hsIL-7, hsIL-8, hsIL-12p70, sTNF-R2, EGFR, and
HGF. Values were significantly lower in serum than
EDTA plasma for IL-4 and IFNg.
Spearman correlation coefficients for EDTA plasma vs.
serum measurements are also shown in Table 2. High
correlations (rs ranging from 0.80 to 0.98) were observed
for hsIL-1b, hsIL-8, IL-12p40, CRP, and sTNF-R2. Most
other correlations were above 60%, although seven mar-
ker assays demonstrated low correlations (rs <0 . 5 )
between paired plasma and serum samples (IL-4, hsIL-4,
sIL-6R, IFNa, IFNg, EGFR and G-CSF).
Comparison of Regular and High-Sensitivity Assays
A subset of 11 cytokines (IL-1b,I L - 2 ,I L - 4 ,I L - 5 ,I L - 6 ,
IL-7, IL-8, IL-10, IL-13, TNFa and IFNg) were measured
in EDTA plasma samples using both high-sensitivity and
regular assays. Regular assays were limited in their abil-
ity to detect some of the markers as compared to high
sensitivity assays and were more likely to require extra-
polation below the standard curve (Table 3). Spearman
correlation coefficients for the two assay types were low
(rs < 0.5) for all markers, and all were non-significant
except for IL-8. The average Spearman correlation coef-
ficients estimated using the bootstrap method (data not
shown) were not appreciably different from the coeffi-
cients estimated using all available plasma samples.
Discussion
We found that 22 cytokines and growth factors were
detectable in over 70% of EDTA plasma samples and
had ICCs of at least 0.53, indicating that for these mar-
kers, a single measurement is representative of an indivi-
dual’s average level (at least over a 2-year period),
relative to other individuals. Of the 21 marker assays
that had insufficient ICCs or which yielded undetectable
values for more than 30% of the samples, 11 markers
(IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-13,
TNFa,a n dI F N g) could be measured reliably using an
alternative high-sensitivity assay.
Our ICC estimates apply to a nested case-control
study in which samples from cases and their matched
controls are measured in the same laboratory batch.
Including samples of case-control matched sets in the
same batch has the advantage of controlling for
between-batch variability, and is the usual approach for
most biomarker studies within cohorts. A limitation of
this study is that our sample size was small, which
resulted in wide confidence intervals for the ICC
estimates.
Several studies have reported that cytokines may be
s e n s i t i v et os a m p l et y p e ,t h o u g ht h em a j o r i t yo ft h e s e
studies compared serum vs. citrate or heparin plasma
[20-24]. In the present study, we observed that EDTA
plasma vs. serum measurements were moderately to
highly correlated (r > 0.60) for 21 of the 26 biomarker
measurements. Median biomarker values were generally
similar for serum and EDTA plasma samples, except for
sIL-6R, hsIL-7, hsIL-8, hsIL-12p70, sTNF-R2, EGFR, and
HGF, which were higher in serum, and IL-4 and IFNg,
which were higher in EDTA plasma.
For markers for which both regular and high-sensitivity
assay kits were available, the high-sensitivity assays were
markedly superior to the regular-sensitivity assays, both
in the percentage of samples that were detectable and in
the reproducibility of the measurements over time. The
correlations between the regular and high-sensitivity
assay measurements were very low. Variation between
assay kits is commonly reported [25], and is likely to
result from technical differences in the design of the
assay [26-28]. For example, the use of different antibodies
between kits could result in lower detection of a cytokine
if one antibody recognizes an epitope that is commonly
bound to a soluble receptor or a serum protein (e.g. albu-
min), or is present in a dimeric or trimeric form [29]. For
the purposes of this study, kits were selected because
they had sufficient assay sensitivity (minimum detectable
concentrations), precision (intra- and inter-batch varia-
tion), and accuracy (% recovery of spiked serum samples)
according to validation data provided by the manufac-
turers or through laboratory validation of the in-house
assays. Based on the sensitivity and recovery-rate data
provided by the manufacturers, we expected that the
Millipore high-sensitivity assay would substantially
improve detection rates over the regular sensitivity assay.
Other reports on the validity of various multiplex assays
in relation to other platforms (e.g. ELISAs or RIAs) are
available for consideration when selecting a kit
[20,27,30-32]. Studies that compared Luminex to ELISA
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a (n = 18 pairs)
Biomarker Plasma Serum Plasma vs.
Serum Paired
Relative
Difference
(%)
p-value
(Wilcoxon Signed-
Rank Test)
Spearman
Correlation
Coefficient
(rs)
rs
p-value
%
Above
LLD
Median (25%, 75%) %
Above
LLD
Median (25%, 75%) Median (25%, 75%)
Cytokines
hsIL-1b (pg/mL)
b 100 5.1 (3.4, 7.5) 94.4 3.5 (2.5, 8.9) 14 (-14, 42) 0.548 0.83 0.000
hsIL-2 (pg/mL)
b 100 18.8 (9.8, 25.7) 100 17.4 (7.4, 35.6) -2.3 (-39, 38) 0.799 0.69 0.002
sIL-2R (pg/ml)
c 100 658 (602, 746) 100 660 (527, 831) -4.7 (-17, 11) 0.459 0.72 0.001
IL-4 (pg/mL)
c 100 141 (108, 181) 100 113 (96.4, 123) 19 (-3.3, 46) 0.009 -0.02 0.922
hsIL-4 (pg/mL)
b 100 56.3 (27.9, 91.4) 100 63.0 (34.4, 108) -15 (-41, 11) 0.159 0.28 0.265
hsIL-5 (pg/mL)
b 100 2.3 (1.4, 3.1) 94.4 2.6 (0.8, 3.9) 11 (-16, 44) 0.459 0.77 0.000
hsIL-6 (pg/mL)
b 100 20.3 (12.6, 35.7) 100 28.9 (13.3, 43.6) -2.2 (-41, 7.6) 0.369 0.77 0.000
sIL-6R (ng/mL)
c 100 27.5 (26.0, 34.6) 100 59.1 (47.9, 91.9) -102 (-189, -68) 0.000 0.39 0.113
hsIL-7 (pg/mL)
b 100 14 (9, 16.9) 94.4 14.8 (13.3, 18.6) -32 (-80, 5.3) 0.008 0.64 0.006
hsIL-8 (pg/mL)
b 100 10.3 (6, 21.5) 100 13.3 (7.9, 26.2) -20 (-59, -1.8) 0.002 0.90 0.000
hsIL-10 (pg/mL)
b 100 31.8 (19.9, 40.2) 100 25.5 (11.2, 48.8) 20 (-23, 30) 0.442 0.73 0.001
IL-12p40 (pg/mL)
c 100 417 (361, 602) 100 417 (358, 537) -0.4 (-6.9, 3.0) 0.393 0.96 0.000
hsIL-12p70 (pg/mL)
b 100 20.8 (14.8, 32.6) 100 29.1 (16.5, 59.9) -14 (-112, 1.3) 0.030 0.77 0.000
hsIL-13 (pg/mL)
b 100 27.2 (19.6, 33.8) 100 32.6 (22.3, 53) -20 (-56, 14) 0.057 0.66 0.003
CRP (μg/mL)
b 100 20.5 (7.4, 35.7) 100 22.2 (8.6, 40.2) -11 (-20, 4.1) 0.081 0.95 0.000
IFNa (pg/mL)
c 100 42.7 (34.2, 53) 100 37.8 (34.2, 47.3) 4.1 (-20, 31) 0.318 -0.05 0.840
IFNg (pg/mL)
c 100 166 (125, 262) 100 83.0 (73.9, 91.1) 56 (20, 70) 0.000 -0.17 0.500
hsIFNg (pg/mL)
b 100 45.4 (25.4, 61) 94.4 38.4 (18.2, 78.8) 4.1 (-42, 40) 0.927 0.68 0.003
hsTNFa (pg/mL)
b 100 10.7 (9.6, 13) 100 10.4 (8.6, 15) -6.9 (-26, 8.8) 0.196 0.71 0.001
sTNF-R1 (ng/mL)
c 100 1.5 (1.4, 1.8) 100 1.6 (1.1, 2.0) -6.6 (-21, 14) 0.442 0.75 0.000
sTNF-R2 (ng/mL)
c 100 1.4 (1.1, 1.8) 100 1.7 (1.2, 1.9) -5.0 (-12, 0.1) 0.009 0.94 0.000
Growth Factors
EGFR (ng/mL)
d 100 13.7 (12.6, 14.8) 100 18.1 (17.1, 20.2) -28 (-44, -18) 0.000 0.48 0.045
ErbB2 (ng/mL)
d 100 3.6 (3.2, 4.1) 100 3.7 (3.1, 4.0) -6.8 (-9.4, -1.6) 0.142 0.72 0.001
hsGM-CSF (pg/mL)
b 100 21.3 (17.4, 31.3) 94.4 28.7 (19, 53.4) -9.9 (-47, 8.1) 0.174 0.79 0.000
G-CSF (pg/mL)
c 100 125 (99.6, 149) 100 91.4 (83, 123) 9.0 (-13, 34) 0.156 0.45 0.059
HGF (pg/mL)
c 100 230 (205, 307) 100 380 (253, 687) -50 (-165, -20) 0.000 0.72 0.001
Note: LLD = lower limit of detection.
a Limited to the biomarkers for which more than 70% of all the samples were detectable. Values were extrapolated below the standard curve for less than 14% of samples for hsIL-5, IFNa, and IL-6R, but were not
extrapolated for any other markers included in the table. Sixteen markers are not included because more than 30% of samples were undetectable (IL-1b, IL-1RA, IL-5, IL-6, IL-17, VEGF), and/or a high percentage of
the samples were extrapolated below the lowest point on the standard curve (IL-1a, IL-2, IL-7, IL-8, IL-10, IL-13, IL-15, TNFa, EGF, bFGF).
b Kits from Linco/Millipore
c Kit from Biosource.
d Kit developed in-house.
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9in healthy subjects have reported low (for IL-6 and TNFa
in two out of three studies) to high correlations depend-
ing on the cytokine of interest [8,20,33].
For most cytokines, median values were similar or
slightly lower (e.g., hsIL-1b, hsIL-2, hsIL-10, hsIL-13,
hsIFNg, hsGM-CSF) in samples from the clinical
research study subjects (Table 2) versus the NSHDS
subjects (Table 1). On the other hand, median CRP and
HGF values were almost 50% higher in the clinical
research subjects than the NSHDS subjects. It is unlikely
that this difference between study groups is due to dif-
ferences in storage time (on average 5-10 years shorter
for clinical research subjects) or sample processing,
since both of these markers are known to be stable dur-
ing long term storage, freeze thaw cycles, and under dif-
ferent sample processing conditions [34-36]; rather it is
likely reflective of differences in participant characteris-
tics, in particular, age (clinical research subjects were an
average of 23 years older).
Samples with florescence intensity values below back-
ground may actually have low cytokine values and could
potentially be imputed for epidemiological studies. CVs,
ICCs, and Spearman correlation coefficients did not dif-
fer when we set the florescence intensity values that
were below background to zero rather than missing.
Investigators should examine the effect of classifying
subjects with values below background as having low
cytokine values vs. missing values on measures of asso-
ciation and report any observed differences.
We previously evaluated the temporal reliability of
these marker assays in serum samples from women in
the prospective New York University Women’sH e a l t h
Study cohort. Six markers met our a priori criteria, ie
detectable in over 40% of samples and ICC threshold of
0.55, in the present study of EDTA plasma that did not
make this cutoff in the serum reliability study: sIL-6R
(ICC = 0.52 in the serum study), and sIL-2R, IL-15,
hsIFNg, G-CSF, and bFGF (not detectable in over 40%
of the serum samples) [9]. Two markers that met the
ICC cutoff value of 0.55 in the previous serum study
(IL-1RA ICC: 0.57 and sTNF-R1 ICC: 0.68) did not
meet this criterion in the present EDTA plasma study.
This suggests that the ICCs for these assays may be dif-
ferent for serum and plasma, though the sample size of
the current plasma study was small, and thus the confi-
dence intervals were fairly wide. Although we did not
have information on a number of potential covariates of
interest for the present study (nor the power to evaluate
the influence of these covariates on cytokines given our
small sample size), the report on serum cytokines found
that adjustment for covariates (age at blood donation,
order of blood donation, blood storage time, menopau-
sal status, phase of menstrual cycle (for premenopausal
w o m e n ) ,B M I ,e t h n i c i t y ,m e d i c a t i o nu s e ,a l c o h o lc o n -
sumption and smoking status) did not change the ICC
estimates appreciably [9].
We found that 22 out of the 31 biomarkers evaluated
in the current report were detectable in a majority of
samples, temporally reliable over an average of 2 years
(ICC ≥ 0.53), and measured reproducibly (CV <10%).
These results suggest that a single measurement of
these biomarkers may be used in epidemiologic studies
Table 3 Spearman correlations between the regular and high-sensitivity assays
a, NSHDS and clinical research study
subjects combined (n = 54 samples)
Biomarker LLD (pg/mL) % of samples above LLD % of samples above LLD
that required
extrapolation
b
n samples used
to compute rs
Spearman
correlation
coefficient (rs)
rs p-
value
Regular
assay
High-
sensitivity
assay
Regular
assay (%)
High-
sensitivity
assay (%)
Regular
assay (%)
High-
sensitivity
assay (%)
IL-1b 15 0.06 41 100 41 0 22 0.17 0.45
IL-2 6 0.16 52 100 64 0 28 0.18 0.36
IL-4 5 0.13 100 100 0 0 54 0.06 0.65
IL-5 3 0.01 0 100 N/A 2 N/A N/A N/A
IL-6 3 0.10 35 100 68 0 19 0.35 0.13
IL-7 10 0.12 50 98 93 0 27 0.11 0.59
IL-8 3 0.11 100 100 26 0 54 0.45 0.0007
IL-10 5 0.15 83 100 91 0 45 0.23 0.13
IL-13 10 0.48 98 100 81 0 53 -0.13 0.37
TNFa 10 0.05 100 100 66 0 54 0.15 0.28
IFNg 5 0.29 100 100 0 0 54 0.08 0.56
Note: All available plasma samples were used for these analyses, i.e., a maximum of 36 samples for the NSHDS and 18 samples for the clinical research subjects.
a Regular assay kit from Biosource and high-sensitivity (hs) assay kit from Linco/Millipore
b Values were extrapolated beyond the lowest point on the standard curve if their florescence intensity reading was above background florescence intensity. If
florescence intensity was less than background florescence intensity, values were considered to be below the lower limit of detection.
Clendenen et al. BMC Research Notes 2010, 3:302
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Page 7 of 9using banked EDTA plasma samples collected before
disease diagnosis to evaluate risk.
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